Providing Strategic business development and clinical site consulting development to three separate global companies. Clients range from small early-stage development companies to larger private equity firms seeking to acquire or merge their clients in USA, Europe and Asia-Pacific. Clients looking to contract with CRO’s, SMO’s and site management services across multiple therapeutic areas.

Joined Apex Innovative Sciences in February 2022 in this role. Apex acquired by CenExel in July 2022. Responsible for new business acquisition, expansion of therapeutic reach, client servicing of existing and past clients. CenExel is the largest wholly owned site network in the USA bringing decades of expertise in conducting Phase I-IV clinical trials for pharmaceutical and biotechnology sponsors in many indications: central nervous system, neurology, psychiatry, addiction, metabolic, infectious disease, vaccine, gene therapy, rare disease, ophthalmic, pain, and more. Included are Asian bridging studies. Client base includes US and biotech companies in EU and Asia both small and large. Targets met each quarter I have been at the company.

CBD Emporium is a privately held company with over 25 locations throughout the United States. Premier source for quality CBD products and offers a diverse selection of best-of-industry brands and its own brand labeled products, derived from medical-grade organic hemp plants.President, CBD Emporium™ Franchise Group Jan 2020 – Mar 2022 In October 2020, CBD Emporium announced the launch of a franchise division to open doors in Q1 of 2021. Identified as an ideal candidate, I was appointed President of the group. COVID-19 delayed progress in the longer-term plan of wide US expansion.

As COO, managing the execution of the company’s aggressive growth plan. Only 18 months old, the company already has 25 outlets, 100 planned by close of Q4-20 and 300 by Q3-2022. Rapid increase in direct distribution, partners and online presence serving diverse market segments.

Leading redevelopment and support of western USA market presence for AES. Development of clinical programs through the innovative deployment of AES’s global site network. Successfully developed a territory and accounts previously closed to the company with largest west coast diverse health-care companies in potential multi-drug development deals.Achievements:Pipeline: additions of $75M in a mix of therapeutic areasClosed sales: $37M in trial work including full service and mixed services (enrollment and clinical services)

Brought visibility to the company, building and growing relationships and access while expanding sales pipeline for a company new to the clinical research space. Territories: western US, Canada and the Pacific Rim including Australia, Korea and Japan. Successfully worked closely with biotech, dietary supplement, cosmetic and device companies.Achievements:- Opening of presence with companies in western US previously not open to InClinica.- Pipeline opportunities in CA, UT, AZ, CO, OR, Korea, Australia of $75M.- Contracts in excess of $18M closed.

Appointed as VP Operations, rapidly promoted to President of newly acquired Vitalea Science. Led a team of 15 staff in providing analytical services to biotech and large pharma companies.Achievements & Milestones: Restructured operations, reversed financial decline, exceeded growth goals within the first 12 months. Exceeded target revenue goal by 145% in first year – from loss to $3M net revenue. Increased companies’ competitive edge in US, Korea and Japan. Worked with Univ of Utah’s Technology & Venture Commercialization group on clinical development deals with several their ventures seeking development partners.  Closed deals with companies in USA, S. Korea and Japan. Small and large biotech, pharma, CRO’s & diagnostic companies. Contracted with biopharma companies in CA, OR, WA, TX, MA, NY, FL, NC, IL, Pipeline contracts in excess of $18M closed at the time of leaving company.

A new role created in once dormant territory. Took leadership role within core regional biotech organization.to further the company’s presence in the market. Built robust revenue pipeline with cumulative multiyear contracts globally. Broadened market opportunities in small biopharma. Acted as lead on internal committee for implementation of customer relationship management system to advance and track global business development.

Appointed in position to build US operations and execute business development strategy for US. Headed up a team of 18 direct reports covering all our services. Stabilized the US operation and retained all existing accounts after a period of flagging management and stagnant growth. Added new accounts. Built visibility, strong market presence and solidified a known entity with a viable presence that persists 10+ years later; helped set stage for later acquisition because of US operational successes.

Transitioned into a business development role after having previously represented a key customer, Abraxis. Accountable for developing accounts in greater southwestern US areas and Pacific Rim. Sought new clients for Phase I, FIM Phase I, II, III trials and post-marketing initiatives. - Expanded an underdeveloped account base to exceptional levels for this established company. Sold more than $46M in services in first year.

Under direction of CEO Dr. Patrick Soon-Shiong. Operational management role. Participated in negotiation of joint ventures, investments and other new business initiatives. Worked on contract and budget negotiations for clinical trials and sponsored and collaborative research in the US, Europe, China and Russia. Managed negotiation and acquisition of two clinical trial management and document management systems that were crucial to project management, compliance objectives and filings with FDA. Managed In-licensed compounds for clinical development from UCLA, Scripps, Buck Foundation & other academic groups.

Member of founding leadership team. Grew this new company in a revolutionary new space in the European market as the exclusive financial portal for major internet service providers. Oversaw launch and business development of UK financial portals and pan-European ventures in 8 countries over 2 years. - Closed deals with some of the most prominent internet services in Europe and closed rev-sharing deals with widely known telecommunications companies. - Launched websites across eight countries in Europe.